TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Technique Plus Sylys® Surgical Sealant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 22 years of age~* Be scheduled for a stapled colorectal or ileorectal anastomosis procedure with or without diverting stoma~* Agree to return for all follow-up evaluations and procedures specified in the protocol~* Understand and give informed consent~Exclusion Criteria:~* Albumin \< 3~* ASA ≥ 4~* Neutropenia ≤ 800~* Pregnancy~* The following conditions involving compromised immune system: AIDS (HIV positive not excluded), neutropenia~* Known blood clotting disorder requiring treatment~* Any condition known to effect wound healing, such as collagen vascular disease~* Have known or suspected allergy or sensitivity to any test materials or reagents~* Concurrent use of fibrin sealants or other anastomosis care devices~* Surgery for emergency abdominal indications~* Has undergone a colorectal anastomosis procedure in the previous two months~* Has an emergent infection related to a previous colorectal anastomosis procedure~* Is scheduled to undergo a Hartmann's procedure~* Is scheduled to undergo trans-anal endoscopic microsurgery (TEM) Is participating in another medical device trial related to colorectal anastomosis

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test- Treatment with Sylys Surgical Sealant (Type: EXPERIMENTAL): Standard closure plus treatment with Sylys Surgical Sealant
- Control- Standard of Care (Type: NO_INTERVENTION): Control group is standard closure of anastomosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exercise for Allogeneic Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hematological cancer, e.g. AML, CLL, MM~* Scheduled for allo-HCT at the University Clinic Heidelberg or other cooperation sites within the next 4-12 weeks~* Patients ≥ 18 years of age~* Sufficient German language skills~* Willing/ able to train at the provided exercise facilities twice per week and to take part in the scheduled testing~* Signed informed consent~Exclusion Criteria:~* Heart insufficiency \> NYHA III or uncertain arrhythmia~* Uncontrolled hypertension~* Severe renal dysfunction (GFR \< 30%, Creatinine\> 3mg/dl)~* Reduced standing or walking ability~* Insufficient hematological capacity (either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL)~* Any other comorbidities that preclude participation in the exercise programs~* Engaging in systematic intense exercise training (at least 1h twice per week)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise (Type: EXPERIMENTAL): Exercise Intervention, moderate to high-intensity endurance and resistance exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect and Tolerability of Lactobacillus Rhamnosus GG LA801 for the Preventive Nutritional Care of Nosocomial Diarrhea in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed by the patient's legal guardian(s) for study enrollment;~* Aged 1 to 24 months ;~* Admitted to the hospital for reasons other than diarrhea;~* Stayed in the Short Stay Unit, SSU, for a minimum duration of 6h.~Exclusion Criteria~* With history of gastroenteritis in the 2 weeks before hospitalization;~* With symptoms suggesting an ongoing gastroenteritis or other intestinal disease;~* Use of probiotics or prebiotics within 7 days before admission;~* With immunodeficiency, neoplasm or chronic severe illnesses;~* With a previous hospitalization within 15 days;~* With an history of digestive surgery;~* For whom an oral route is impossible;~* Participating at the same time in another clinical trial.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Babybiane Imedia (Type: EXPERIMENTAL): Patients receive Babybiane Imedia once daily during seven days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Acute or chronic hepatitis C~    * Receiving pegylated interferon alfa and ribavirin~ * Metastatic melanoma~    * Receiving ticilimumab~ * Crohn disease~    * Received prior infliximab~Exclusion Criteria:~* Not specified~PATIENT CHARACTERISTICS:~* Not specified~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prevention Education in Caries Formation in Pediatric Patients With Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients who have been recently diagnosed with leukemia~* Patients will also predictably be in primary or mixed dentition~* Patients of Virginia Commonwealth University Medical Center Pediatric Hematology Oncology Clinic~Exclusion Criteria:~* Full permanent dentition~* Primary language is not English~* Children in the custody of the state with no parent or legal guardian present to sign consent

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Group I (standard prevention education) (Type: ACTIVE_COMPARATOR): Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
- Group II (standard and one-on-one education, consultation) (Type: EXPERIMENTAL): Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient~* Patient undergoing elective colorectal surgery (diverticulitis, malignant or benign tumor, inflammatory intestinal disease, re-establishing continuity, endometriosis, or other)~* Bowel continuity is restored immediately after surgery, with or without a protective stoma.~* Patient with proper understanding who has been informed about the study, and who has consented to being part of the study~Exclusion Criteria:~* Adult under guardianship~* Patient who is not covered under the national health system~* Women who are pregnant or breastfeeding~* Colorectal resection with concomitant hyperthermic intraperitoneal chemotherapy~* Patient under long term corticosteroid therapy~* Preoperative natremia \> 147 mmol/L~* Hypokalemia (\< 3,3 mmol/L)~* Patient with a contraindication to Methylprednisolone Mylan® :~  * Active infection~ * Active viral disease (namely hepatitis, herpes, varicella, shingles),~ * A psychotic condition that is not currently treated with medication,~ * Vaccination with a live vaccine or live attenuated within the last 3 months,~ * Hypersensitivity to methylprednisolone or to any of the excipients found in Methylprednisolone Mylan®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronotherapy in Acute Multiple Sclerosis (MS) Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing remitting MS~* EDSS-score before the actual attack \< 6.0~* Acute MS-attack with indication for treatment with steroids~* Symptoms \>24 hours \< 4 weeks~* Age 18 years or older~Exclusion Criteria:~* Prior enrollment in this study~* Ongoing serious infection that is a contraindication for treatment with steroids~* Pregnancy~* Medical situations (prior acute diseases) where treatment with intravenous steroids over short period of time is contraindicated or not favorable.~* Enhanced cognitive dysfunction~* Treatment with p.o or i.v steroids within 3 weeks prior to date of inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
- 2 (Type: ACTIVE_COMPARATOR): Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Patients with DS and those without DS receiving BIS monitoring~  * Children between the ages of 2 and 17 years old (inclusive)~ * Patients scheduled for unilateral or bilateral tympanostomy (ear tube placement) at Penn State Hershey Medical Center~ * Patients with American Society of Anesthesiologists (ASA) physical status I, II and III~ * Eligible for standard general anesthesia technique protocol as determined by anesthesia provider(s)~Exclusion Criteria:~* Patients with congenital diseases/anomalies except Down's Syndrome~* Patients with myotonic dystrophies or other neurodegenerative diseases~* Patients with cerebrovascular accidents (strokes)~* Patients not receiving BIS monitoring~* Pregnant patients~* Patients with allergic skin reactions to electrode patches~* Patients 18 years of age and greater

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Normal (Type: None): This is the group with no neurological problems or syndrome
- Down syndrome (Type: None): This is the group with Down syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of a Neurodegenerative Disorder including frontotemporal dementia, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), dementia with Lewy bodies (DBL), vascular cognitive disorders, or Huntington's disease, at least 3 months prior to Baseline~* The participant has behavior from 2 of the 3 categories of disinhibited behavior from the definition of the behavioral variant of frontotemporal dementia~* The behavioral changes are not due to a pre-existing major psychiatric disorder (e.g., schizophrenia, bipolar disease, etc.) and are not due to the direct effect of systemic illness, drug action, or substance use~* Disinhibition scale score of ≥4 on the 3 core disinhibition items of the Frontal Behavioral Inventory (FBI) at Screening and Baseline~Exclusion Criteria:~* Participants with symptoms of disinhibition that is not secondary to Neurodegenerative Disorders~* Participants with myasthenia gravis~* Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy \[except skin basal-cell carcinoma or untreated prostate cancer\], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo drug to be taken twice a day for 6 weeks
- AVP-786 (Type: ACTIVE_COMPARATOR): Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain After Proximal Digital Amputation Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring single finger amputations at the level of the proximal interphalangeal joint or proximal (i.e., closer to the body than this joint).~* Patients have the capacity to complete the informed consent process~Exclusion Criteria:~* Patients less than 18 years of age, prisoner, or other vulnerable population~* Patients with significant concomitant ipsilateral extremity injuries that would confound study~* Patients requiring emergent, staged (guillotine-type) amputations of any kind

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traction Neurectomy (Type: ACTIVE_COMPARATOR): Traction neurectomy - of digital sensory nerves at the time of amputation.
- Targeted Muscle Reinnervation (Type: EXPERIMENTAL): Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
- Regenerative Peripheral Nerve Interface (Type: EXPERIMENTAL): Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Conventional renal cell cancer with a pathological diagnosis~* Metastatic disease~* Consent form signed~* social security regimen affiliated~Exclusion Criteria:~* Other cancer treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CA9 level (Type: None): Serum and urinary CA9 level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Briefly, the diagnosis of glaucoma is based on the presence of 2 or more of the following findings: 1) glaucomatous optic disc damage, defined as the presence of optic disc excavation, diffuse or focal neuroretinal rim thinning or notching, localized or generalized retinal nerve fiber layer (RNFL) thinning; 2) visual field defects consistent with glaucoma; and 3) IOP ≥ 22 mmHg.~* Patients with glaucoma who have been advised to undergo TCNR of a failed trabeculectomy bleb by a glaucoma specialist at Northwestern Medicine~* History of failed trabeculectomy (based on clinical features of the trabeculectomy bleb and elevated intraocular pressure)~* Patients can have history of other glaucoma surgery or cataract surgery~* The diagnosis of glaucoma is based on the presence of 2 or more of the following findings: 1) glaucomatous optic disc damage, defined as the presence of optic disc excavation, diffuse or focal neuroretinal rim thinning or notching, localized or generalized RNFL thinning; 2) visual field defects consistent with glaucoma; and 3) IOP ≥ 22 mmHg.~Exclusion criteria~* Age younger than 18 years;~* Secondary causes of glaucoma (e.g., iridocyclitis, trauma);~* Any evidence of corneal or conjunctival pathology adjacent to filtration bleb that could influence AS-OCT image~* Patients who did not undergo surgery or have adequate follow up~* Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and vulnerable populations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AS-OCT and iOCT (Type: OTHER): This prospective study will include approximately 25 patients with open-angle glaucoma who will undergo TCNR of trabeculectomy bleb by a glaucoma specialist at Northwestern Medicine. These patients will have a history of glaucoma and failed trabeculectomy bleb (as evidenced by clinical features and elevated IOP). During routine clinic visit, the patient will undergo lit lamp grading of bleb by Indiana Bleb Appearance Grading Score (IBAGS). Subjects who agree to participate and provide written informed consent will undergo AS-OCT imaging (Spectralis OCT, Heidelberg) of the bleb. During their operation, the Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), a commercially available device will be utilized to visualize and evaluate the morphology of the trabeculectomy bleb at the start and conclusion of the case.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Managing Insulin Pumps for Exercise (Study 2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged between 18 and 65 years~* Diagnosed with Type 1 diabetes mellitus~* Treated with CSII for at least 3 months~* Exercises regularly for more than 1 hour per week~Exclusion Criteria:~* People with any one of the following complications of diabetes:~  * stage 2+ diabetic retinopathy~ * renal impairment (with creatinine \>150micromol/l)~ * known history or symptoms of cardiovascular disease~ * foot ulceration~ * peripheral vascular disease~* Known pregnancy or breastfeeding~* Untreated or unstable respiratory disease~* Known hypoglycaemia unawareness~* Treatment with drugs known to interfere with glucose metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 90 minutes (Type: EXPERIMENTAL): Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
- 60 minutes (Type: EXPERIMENTAL): Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
- 30 minutes (Type: EXPERIMENTAL): Basal insulin infusion reduced to normal 30 minutes prior to exercise
- Start (Type: EXPERIMENTAL): Basal insulin infusion reduced to 50% of normal at the start of exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues